News

Femta Pharmaceuticals (Femta) and Lonza have entered into a manufacturing services agreement to facilitate the development and cGMP manufacturing of FM101. FM101 is a monoclonal antibody in late

Gilead Sciences (Gilead) has reported that DAR-312 (DORADO-AC), a Phase III clinical trial evaluating darusentan did not achieve its co-primary efficacy endpoints of change from baseline to week

Human Genome Sciences (HGS) has announced that Novartis has submitted a Marketing Authorization Application (MAA) to the EMEA for approval to market Joulferon (albinterferon alfa-2b, known in the

Advaxis is going to collaborate with the Gynecologic Oncology Group (GOG), a collaborative research group of the National Cancer Institute (NCI), in a multicenter, phase II clinical trial

EpiCept has provided an update on new clinical developments and other initiatives related to Ceplene (histamine dihydrochloride) therapy, approved in the EU, for the remission maintenance and prevention

The US Patent and Trademark Office (USPTO) has issued a notification to NovaDel Pharma (NovaDel) for a new US Patent No. 7632517, entitled Buccal, Polar and Non-polar Spray

Arkray has re-introduced the CLIA waived DiaScreen 50 Urine Chemistry Analyzer. The company’s DiaScreen 50 enables easy in-office urine testing. It provides instrument read results that eliminate color

Elan and Transition Therapeutics have notified clinical investigators of modifications to the Phase II study AD201, and open label extension study AD251, for ELND005, a compound being developed

Amylin Pharmaceuticals (Amylin), Eli Lilly and Alkermes have reported positive results from a head-to-head study comparing exenatide once weekly, an investigational diabetes therapy, to Byetta (exenatide) injection taken